Publications

2015

Lidewij C.M. Wiersma, Joost H.C.M. Kreijtz, Stella E. Vogelzang-van Trierum, Geert van Amerongen, Peter van Run, Mechtild Ladwig, Stefanie Banneke, Hubert Schaefer, Ron A.M. Fouchier, Thijs Kuiken, Albert D.M.E. Osterhaus, Guus F. Rimmelzwaan (2015) Virus replication kinetics and pathogenesis of infection with H7N9 influenza virus in isogenic guinea pigs upon intratracheal inoculation doi:10.1016/j.vaccine.2015.08.050

Lidewij C.M. Wiersma, Stella E. Vogelzang-van Trierum, Joost H.C.M. Kreijtz, Geert van Amerongen, Peter van Run, Mechtild Ladwig, Stefanie Banneke, Hubert Schaefer, Ron A.M. Fouchier, Thijs Kuiken, Albert D.M.E. Osterhaus, Guus F. Rimmelzwaan (2015) Heterosubtypic immunity to H7N9 influenza virus in isogenic guinea pigs after infection with pandemic H1N1 virus doi:10.1016/j.vaccine.2015.08.038

Carolien E. van de Sandt, Joost H.C.M. Kreijtz, Martina M. Geelhoed-Mieras, Nella J. Nieuwkoop, Monique I. Spronken, David A.M.C. van de Vijver, Ron A.M. Fouchier, Albert D.M.E. Osterhaus and Guus F. Rimmelzwaan (2015) Differential recognition of influenza A viruses by M158-66 epitope-specific CD8+ T cells is determined by extra-epitopic amino acid residues doi: 10.1128/JVI.02439-15

Carolien E van de Sandt, Rogier Bodewes, Guus F Rimmelzwaan & Rory D de Vries (2015). Influenza B viruses: not to be discounted. Future Microbiology Vol. 10, No. 9, Pages 1447-1465 (doi:10.2217/fmb.15.65)

Lei Deng, Lorena Itatí Ibañez, Veronique Van den Bossche, Kenny Roose, Sameh A. Youssef, Alain de Bruin, Walter Fiers, Xavier Saelens (2015). Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages. PLoS ONE 10(5): e0126650. doi:10.1371/journal.pone.0126650

Rory D. de Vries, Heidi L.M. De Gruyter, Theo M. Bestebroer, Mark Pronk, Ron A.M. Fouchier, Albert D.M.E. Osterhaus, Gerd Sutter, Joost H.C.M. Kreijtz, and Guus F. Rimmelzwaan (2015) Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine. Emerging Infectious Diseases Volume 21, Number 6—June 2015

Rory D de Vries, Arwen F Altenburg & Guus F Rimmelzwaan (2015). Universal influenza vaccines, science fiction or soon reality? Expert Review of Vaccines DOI:10.1586/14760584.2015.1060860

Judith M. Fonville, Pieter L. A. Fraaij, Gerrie de Mutsert, Samuel H. Wilks, Ruud van Beek, Ron A. M. Fouchier and Guus F. Rimmelzwaan. (2015). Antigenic maps of influenza A/H3N2 virus produced with human antisera obtained after primary infection. J Infect Dis. (2015) doi: 10.1093/infdis/jiv367

Bahar Ramezanpour, Esther S. Pronker, Joost H.C.M. Kreijtz, Albert D.M.E. Osterhaus, E. Claassen. (2015). Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis. Vaccine Volume 33, Issue 35, 20 August 2015, Pages 4349–4358

van de Sandt CE, Dou Y, Vogelzang-van Trierum SE, Westgeest KB, Pronk MR, Osterhaus AD, Fouchier RA, Rimmelzwaan GF, Hillaire ML. (2015). Influenza B virus-specific CD8+ T lymphocytes strongly cross-react with viruses of the opposing influenza B lineage. The Journal of General Virology 96: 2061-2073

Lidewij C. M. Wiersma , Guus F. Rimmelzwaan and Rory D. de Vries. (2015) Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Vaccine 2015, 3(2), 239-262.

Sarah De Baets, Judith Verhelst, Silvie Van den Hoecke, Anouk Smet, Michael Schotsaert, Emma R. Job, Kenny Roose, Bert Schepens, Walter Fiers, and Xavier Saelens. (2015) A GFP Expressing Influenza A Virus to Report In Vivo Tropism and Protection by a Matrix Protein 2 Ectodomain-Specific Monoclonal Antibody. PLoS One. 2015; 10(3): e0121491.

Altenburg AF, Rimmelzwaan GF, de Vries RD. (2015) Virus-specific T cells as correlate of (cross-)protective immunity against influenzaVaccine 33(4):500-506

van de Sandt CE, Hillaire ML, Geelhoed-Mieras MM, Osterhaus AD, Fouchier RA, Rimmelzwaan GF. (2015) Human Influenza A Virus-Specific CD8+ T-Cell Response Is Long-lived. J Infect Dis. 2015 Jan 12. pii: jiv018. [Epub ahead of print]

2014

Wagner K, Kwakkenbos MJ, Claassen YB, Maijoor K, Böhne M, van der Sluijs KF, Witte MD, van Zoelen DJ, Cornelissen LA, Beaumont T, Bakker AQ, Ploegh HL, Spits H. (2014) Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activityProc Natl Acad Sci U S A. 111(47):16820-5

J.H.C.M. Kreijtz, L.C.M. Wiersma, H.L.M. Gruyter De, S.E. Vogelzang-van Trierum, G. van Amerongen, K.J. Stittelaar, R.A.M. Fouchier, A.D.M.E. Osterhaus, G. Sutter and G.F. Rimmelzwaan (2014) A single immunization with a modified Vaccinia Virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. The Journal of Infectious Diseases 10.1093/infdis/jiu528

Ioanna Christopoulou, Kenny Roose, Lorena Itatí Ibañez, and Xavier Saelens (2014) Influenza vaccines to control influenza-associated bacterial infection: where do we stand? Expert Review of Vaccine doi:10.1586/14760584.2015.957191

Asisa Volz, Martin Langenmayer, Sylvia Jany, Ulrich Kalinke and Gerd Sutter (2014) Rapid expansion of CD8+ T cells in wildtype and type I interferon receptor deficient mice correlates with protection after low-dose emergency immunization with Modified Vaccinia virus Ankara. Journal of Virology Published ahead of print 9 July 2014, doi: 10.1128/JVI.00945-14

Arwen F. Altenburg, Joost H. C. M. Kreijtz, Rory D. de Vries, Fei Song, Robert Fux, Guus F. Rimmelzwaan, Gerd Sutter and Asisa Volz (2014) Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases. Viruses 2014, 6, 2735-2761; doi:10.3390/v6072735

Consortium

Rationale

Flunivac’s approach

First periodic report